

Ref. No: 2289
Date: 14/01/26
Subject: Diffuse Large B Cell Lymphoma (DLBCL)

REQUEST

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
- R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)
- (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)
- R-GemOX (rituximab, gemcitabine and oxaliplatin)
- Axicabtagene ciloleucel
- Tisagenlecleucel
- Epcoritamab
- Loncastuximab tesirine
- Glocitamab
- Any other SACT

- Stem cell transplant or bone marrow transplant (autologous or allogeneic)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- R-GemOX (rituximab, gemcitabine and oxaliplatin)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Glofitamab
- Any other treatments

Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)?

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatment

RESPONSE

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

19

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - **11**
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - **0**
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) – **<5**
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) - **0**
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) - **0**
- R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) - **<5**
- (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) - **0**
- R-GemOX (rituximab, gemcitabine and oxaliplatin) - **0**
- Axicabtagene ciloleucel - **0**
- Tisagenlecleucel - **0**
- Epcoritamab - **0**
- Loncastuximab tesirine - **0**
- Glofitamab - **0**
- Any other SACT - **<5**
- Stem cell transplant or bone marrow transplant (autologous or allogeneic) - **0**

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta) - **0**
- Tisagenlecleucel - **0**
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - **0**
- R-GemOX (rituximab, gemcitabine and oxaliplatin) - **0**
- Stem cell transplant or bone marrow transplant (autologous or allogeneic) - **0**
- Glofitamab - **0**
- Any other treatments - **0**

Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)?

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel) - **0**
- Stem cell transplant or bone marrow transplant (autologous or allogeneic) - **0**
- Any other treatment - **0**